These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 34371542)

  • 1. [Meta-analysis of the effects of statins on the risk of chronic liver disease and hepatocellular carcinoma].
    Wei J; Lvy JH; Sun XJ; Wu XR
    Zhonghua Gan Zang Bing Za Zhi; 2021 Jul; 29(7):696-701. PubMed ID: 34371542
    [No Abstract]   [Full Text] [Related]  

  • 2. Statins in Hepatitis B or C Patients Is Associated With Reduced Hepatocellular Carcinoma Risk: A Systematic Review and Meta-Analysis.
    Li Z; Li Y; Li X; Zhang L; Zhao N; Du H; Zhou B; Ye Y
    Turk J Gastroenterol; 2022 Feb; 33(2):136-144. PubMed ID: 35115293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Meta-Analysis of Statin Use and Risk of Hepatocellular Carcinoma.
    Wang Y; Wang W; Wang M; Shi J; Jia X; Dang S
    Can J Gastroenterol Hepatol; 2022; 2022():5389044. PubMed ID: 35356132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipophilic Statins and Risk for Hepatocellular Carcinoma and Death in Patients With Chronic Viral Hepatitis: Results From a Nationwide Swedish Population.
    Simon TG; Duberg AS; Aleman S; Hagstrom H; Nguyen LH; Khalili H; Chung RT; Ludvigsson JF
    Ann Intern Med; 2019 Sep; 171(5):318-327. PubMed ID: 31426090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statin and the risk of hepatocellular carcinoma in patients with hepatitis B virus or hepatitis C virus infection: a meta-analysis.
    Li X; Sheng L; Liu L; Hu Y; Chen Y; Lou L
    BMC Gastroenterol; 2020 Apr; 20(1):98. PubMed ID: 32272891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Letter to the Editor: Statins and Reduced Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B.
    Huang R; Wang J; Wu W; Yan X; Wu C
    Hepatology; 2020 Jun; 71(6):2173-2174. PubMed ID: 31858599
    [No Abstract]   [Full Text] [Related]  

  • 7. Statins on hepatocellular carcinoma risk in hepatitis B or C patients protocol for a systematic review and meta-analysis.
    Li Z; Li Y; Li X; Zhang L; Zhao N; Du H; Zhou B; Ye Y
    Medicine (Baltimore); 2018 Aug; 97(34):e11950. PubMed ID: 30142817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can Statin Treatment Reduce the Risk of Hepatocellular Carcinoma? A Systematic Review and Meta-Analysis.
    Chang Y; Liu Q; Zhou Z; Ding Y; Yang M; Xu W; Chen K; Zhang Q; Wang Z; Li H
    Technol Cancer Res Treat; 2020; 19():1533033820934881. PubMed ID: 32552476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statins and risk reduction in hepatocellular carcinoma: fact or fiction?
    Singh PP; Singh S
    J Clin Oncol; 2012 Jul; 30(20):2569-70; author reply 2570-2571. PubMed ID: 22689810
    [No Abstract]   [Full Text] [Related]  

  • 10. The benefit of statins in chronic hepatitis C patients: a systematic review and meta-analysis.
    Zheng YX; Zhou PC; Zhou RR; Fan XG
    Eur J Gastroenterol Hepatol; 2017 Jul; 29(7):759-766. PubMed ID: 28240613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis.
    Singh S; Singh PP; Singh AG; Murad MH; Sanchez W
    Gastroenterology; 2013 Feb; 144(2):323-332. PubMed ID: 23063971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection.
    Tsan YT; Lee CH; Wang JD; Chen PC
    J Clin Oncol; 2012 Feb; 30(6):623-30. PubMed ID: 22271485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative efficacy of tenofovir and entecavir in nucleos(t)ide analogue-naive chronic hepatitis B: A systematic review and meta-analysis.
    Chen MB; Wang H; Zheng QH; Zheng XW; Fan JN; Ding YL; Niu JL
    PLoS One; 2019; 14(11):e0224773. PubMed ID: 31751366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of statin treatment with hepatocellular carcinoma risk in end-stage kidney disease patients with chronic viral hepatitis.
    Kim HW; Joo YS; Kang SC; Koh HB; Han SH; Yoo TH; Kang SW; Park JT
    Sci Rep; 2022 Jun; 12(1):10807. PubMed ID: 35752695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of aspirin and statin use with the risk of liver cancer in chronic hepatitis B: A nationwide population-based study.
    Choi WM; Kim HJ; Jo AJ; Choi SH; Han S; Ko MJ; Lim YS
    Liver Int; 2021 Nov; 41(11):2777-2785. PubMed ID: 34242482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between Statins Types with Incidence of Liver Cancer: An Updated Meta-analysis.
    Zhang X; Lou D; Fu R; Wu F; Zheng D; Ma X
    Curr Med Chem; 2024; 31(6):762-775. PubMed ID: 37393552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pleiotropic effects of statins in the diseases of the liver.
    Janicko M; Drazilova S; Pella D; Fedacko J; Jarcuska P
    World J Gastroenterol; 2016 Jul; 22(27):6201-13. PubMed ID: 27468210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effectiveness of TDF versus ETV on incidence of HCC in CHB patients: a meta analysis.
    Zhang Z; Zhou Y; Yang J; Hu K; Huang Y
    BMC Cancer; 2019 May; 19(1):511. PubMed ID: 31142283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statin and the risk of hepatocellular carcinoma and death in a hospital-based hepatitis B-infected population: A propensity score landmark analysis.
    Hsiang JC; Wong GL; Tse YK; Wong VW; Yip TC; Chan HL
    J Hepatol; 2015 Nov; 63(5):1190-7. PubMed ID: 26208777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic review with network meta-analysis: statins and risk of hepatocellular carcinoma.
    Zhou YY; Zhu GQ; Wang Y; Zheng JN; Ruan LY; Cheng Z; Hu B; Fu SW; Zheng MH
    Oncotarget; 2016 Apr; 7(16):21753-62. PubMed ID: 26943041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.